This article first appeared on GuruFocus .
Release Date: November 05, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Ambea AB ( STU:6MA ) reported strong financial performance with a 16% increase in net sales, driven by 13% acquired growth and 4% organic growth.
-
The company achieved an adjusted EBITA margin of 9.9%, surpassing its profitability target of 9.5%.
-
Ambea AB ( STU:6MA ) continues to expand its operations with a robust pipeline of new care facilities, including 4 new nursing homes and several expansions planned over the next 12 months.
-
The company has successfully integrated acquisitions, particularly in Finland, and expects positive earnings impact from recent acquisitions by 2026.
-
Ambea AB ( STU:6MA ) has launched a share buyback program, indicating strong cash flow and financial flexibility to invest in growth and return value to shareholders.
Negative Points
-
The company faced negative currency effects of 1%, which impacted overall growth.
-
In Norway, Ambea AB ( STU:6MA ) experienced a decline in earnings due to fluctuating occupancy and staffing challenges, resulting in a lower EBITA margin.
-
The recent acquisition in Finland's child welfare segment is expected to have startup and integration costs, delaying positive margin contributions in the near term.
-
Clara, one of Ambea AB ( STU:6MA )'s segments, saw a 9% decrease in net sales due to lower demand, impacting profitability.
-
The company anticipates continued fluctuations in demand in Norway, which may affect short-term operational efficiency and profitability.
Q & A Highlights
-
Warning! GuruFocus has detected 8 Warning Signs with STU:6MA.
-
Is STU:6MA fairly valued? Test your thesis with our free DCF calculator.
Q: When you announced the acquisition, you mentioned a margin of around 11.5% on a full-year basis. Now, in Q3, the margin looks quite strong. Are you tracking at a higher level, perhaps around 12% or above? A: We are only two quarters into the acquisition and have not fully experienced the seasonality effects yet. Q4 is typically weaker in Finland due to banking holidays. We are cautious and maintain our previous expectation of 11.5% as the run rate level going forward. - Unidentified_3
Q: How should we think about growth and potential to increase profitability for next year? A: Growth opportunities for the acquisition come from organic growth with new care units and acquisitions. We have two new signed contracts for openings in Q4 next year. We are actively looking at more acquisitions in Finland and expect to sign more contracts and close more acquisitions in the coming quarters. - Unidentified_2
Q: Regarding the fluctuations in demand for Stendi, should we expect a lesser impact in the coming quarters? A: We had a strong Q4 last year due to a one-off item, which we won't see this year. We will continue to optimize our portfolio and work on operational efficiency. However, due to high staffing requirements in Norway, changes will follow with some delay. We believe a good market level profitability in Norway is around 8-9% EBITA margin. - Unidentified_2
Q: Should the share buyback program be seen as an indicator of lower M&A appetite in the near term? A: No, the share buyback program will not affect our M&A plans. The buyback will affect leverage by 0.2 times, but we still have good cash flow to make all planned acquisitions. - Unidentified_3
Q: Can you provide some color on your M&A pipeline outside of Finland? A: The strongest pipeline is in Sweden, with several small and mid-size opportunities for qualitative build-on acquisitions. We are looking in all markets and segments for good quality opportunities, with the most attractive pipeline currently in the Nida and Validia segments. - Unidentified_2
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
